help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kee Shin, Y.
Right arrow Articles by Hoe Park, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kee Shin, Y.
Right arrow Articles by Hoe Park, S.
(American Journal of Pathology. 2001;158:1473-1480.)
© 2001 American Society for Investigative Pathology

Regular Articles

Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus

Young Kee Shin*{dagger}, Eun Young Choi*, Seok Hyung Kim*, Junho Chung{ddagger}, Doo Hyun Chung*, Weon Seo Park§, Kyeong Cheon Jung, Heung Sik Kim||, Seonyang Park**, Hee Jin Kim{dagger}{dagger}, Myoung Hee Park{dagger}{dagger}, Chang Ki Min{ddagger}{ddagger}, Chun Choo Kim{ddagger}{ddagger} and Seong Hoe Park*

From the Departments of Pathology,*
Internal Medicine,**
Clinical Pathology,{dagger}{dagger}
and Biochemistry,{ddagger}
Seoul National University College of Medicine, Seoul; DiNonA Inc.,{dagger}
Suwon; the Department of Pathology,§
Kangwon National University College of Medicine, Chunchon; the Department of Pathology,
Hallym University College of Medicine, Chunchon; the Catholic HSCT Center,{ddagger}{ddagger}
St. Mary’s Hospital, The Catholic University of Korea, Seoul; and the Department of Pediatrics,||
Keimyung University College of Medicine, Taegu, Korea

The identification of immunophenotypic markers with restricted expression has long been a critical issue in diagnostic and therapeutic advances for acute leukemias. We previously developed a monoclonal antibody against a new thymocyte surface antigen, JL1, and showed that JL1 is expressed in the majority of acute leukemia cases. In this study, using multiparameter flow cytometric analyses, we found that JL1 was uniquely expressed in subpopulations of normal bone marrow (BM) cells, implying the association of JL1 with the differentiation and maturation process. Although CD34+ CD10+ lymphoid precursors and some of maturing myeloid cells express JL1, neither CD34+ CD38-/lo nor CD34+ AC133+ noncommitted pluripotent stem cells do. As for the myeloid precursors, CD34+ CD33+ cells do not express JL1. During lymphopoiesis, JL1 on the earliest lymphoid precursors disappear in the CD20+ sIgM+ stage of B-cell development or after CD1a down-regulation in thymocytes. Despite the highly restricted expression of JL1 in normal BM cells, most of the leukemias express JL1 irrespective of their immunophenotypes. These results indicate that JL1 is not only a novel differentiation antigen of hematopoietic cells, but also a leukemia-associated antigen. Therefore, we suggest that JL1 be a candidate molecule in acute leukemia for the diagnosis and immunotherapy that spares the normal BM stem cells.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society for Investigative Pathology.